Funding
Vitacore pursues grant funding from UK and international funders whose strategic priorities match the research agenda. Translation pathways include IP licensing, expert consulting, and spinout formation where the science supports it.
i4i Product Development · 2026/27 strategic funding · Health Technology Assessment
Mapped to topics RC-01, RC-03, RC-05, RC-08, RC-12 and hard problems HP-02, HP-03. NIHR's analogue-to-digital shift and decentralised monitoring priorities align directly with the Vitacore programme.
Theoretical Computer Science · Trustworthy Autonomous Systems · Cross-disciplinary calls
Mapped to HP-01, HP-04 and topics RC-04, RC-10. Vitacore's formal-methods identity matches EPSRC's safety-of-AI programme. Cross-disciplinary calls reward boundary-crossing work.
Biomedical Catalyst · Sustainable Infrastructure
Mapped to RC-05, RC-06, RC-10, RC-12. Innovate UK funds translational work — particularly where IP can be commercialised through licensing or spinout.
Neurological Disorders · Computational medicine
Mapped to RC-07, RC-12 and HP-05. MRC's neurological programme supports tremor characterisation, neuromodulation, and digital twin clinical work.
Digital health · Computational medicine
Mapped to HP-05 and RC-11. The Discretionary Award and Computational Medicine programme align with causal twin work.
Defence and Security Accelerator
Mapped to HP-02 (military TBI), RC-08 (resistant-cohort monitoring). Field-condition clinical sensing is an active DASA call area.
Formal specification methodologies licensable to medtech companies seeking MHRA compliance under the 2026 AI device framework. Provisional patents on signal-fusion algorithms (RC-05), sepsis trajectory automata (RC-03), RF sensing architecture (RC-08), and neuromodulation closed-loop specifications (RC-12).
Formally verified clinical early-warning platform as a software medical device under the MHRA 2026 framework. SEIS/EIS eligible structure once formal registration completes.
Independent technical assessment via expert networks — telecommunications-to-clinical signal processing, medical device regulatory landscape, wearable sensor assessment for investors.
Phase 3 original datasets — wearable physiological, acoustic-emission, RF sensing, formal verification traces — licensed for academic research at no cost and to commercial users at fair-market rates.